{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:29:16Z","timestamp":1787696956595,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02873-8"],"award-info":[{"award-number":["2021\/02873-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02873-8"],"award-info":[{"award-number":["2021\/02873-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02873-8"],"award-info":[{"award-number":["2021\/02873-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02873-8"],"award-info":[{"award-number":["2021\/02873-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02873-8"],"award-info":[{"award-number":["2021\/02873-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12640-024-00724-0","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:19:25Z","timestamp":1734607165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice"],"prefix":"10.1007","volume":"43","author":[{"given":"R.","family":"Ponciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Ap. Del","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"724_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"3","key":"724_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.neuroscience.2003.08.058","volume":"122","author":"OA Andreassen","year":"2003","unstructured":"Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, J\u00f8rgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122(3):717\u2013725. https:\/\/doi.org\/10.1016\/j.neuroscience.2003.08.058","journal-title":"Neuroscience"},{"issue":"2","key":"724_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ncl.2020.01.004","volume":"38","author":"HH Bashir","year":"2020","unstructured":"Bashir HH, Jankovic J (2020) Treatment of Tardive Dyskinesia. Neurol Clin 38(2):379\u2013396. https:\/\/doi.org\/10.1016\/j.ncl.2020.01.004","journal-title":"Neurol Clin"},{"issue":"6","key":"724_CR4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.pnpbp.2008.05.003","volume":"32","author":"M Bishnoi","year":"2008","unstructured":"Bishnoi M, Chopra K, Kulkarni SK (2008) Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 32(6):1473\u20131478. https:\/\/doi.org\/10.1016\/j.pnpbp.2008.05.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"724_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1744-9081-8-12","volume":"8","author":"PJ Blanchet","year":"2012","unstructured":"Blanchet PJ, Parent MT, Rompr\u00e9 PH, L\u00e9vesque D (2012) Relevance of animal models to human tardive dyskinesia. Behav Brain Funct 8:12. https:\/\/doi.org\/10.1186\/1744-9081-8-12","journal-title":"Behav Brain Funct"},{"issue":"11","key":"724_CR6","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1177\/0269881118788830","volume":"32","author":"PS Bloomfield","year":"2018","unstructured":"Bloomfield PS, Bonsall D, Wells L, Dormann D, Howes O, De Paola V (2018) The effects of haloperidol on microglial morphology and translocator protein levels: An in vivo study in rats using an automated cell evaluation pipeline. J Psychopharmacol 32(11):1264\u20131272. https:\/\/doi.org\/10.1177\/0269881118788830","journal-title":"J Psychopharmacol"},{"issue":"13","key":"724_CR7","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/bph.15439","volume":"178","author":"M Bortolanza","year":"2021","unstructured":"Bortolanza M, do Nascimento GC, Raisman-Vozari R, Del-Bel E (2021) Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats. Br J Pharmacol 178(13):2595\u20132616. https:\/\/doi.org\/10.1111\/bph.15439","journal-title":"Br J Pharmacol"},{"issue":"4","key":"724_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/s0306-4522(01)00531-0","volume":"109","author":"MM B\u00fccheler","year":"2002","unstructured":"B\u00fccheler MM, Hadamek K, Hein L (2002) Two alpha (2)-adrenergic receptor subtypes, alpha(2A) and alpha(2\u00a0C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109(4):819\u2013826. https:\/\/doi.org\/10.1016\/s0306-4522(01)00531-0","journal-title":"Neuroscience"},{"issue":"3","key":"724_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU (2018) Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17(3):330\u2013340. https:\/\/doi.org\/10.1002\/wps.20579","journal-title":"World Psychiatry"},{"issue":"4","key":"724_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.9758\/cpn.2020.18.4.493","volume":"18","author":"SN Caroff","year":"2020","unstructured":"Caroff SN (2020) Recent Advances in the Pharmacology of Tardive Dyskinesia. Clin Psychopharmacol Neurosci 18(4):493\u2013506. https:\/\/doi.org\/10.9758\/cpn.2020.18.4.493","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"724_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","volume":"159","author":"MG Cascio","year":"2010","unstructured":"Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159(1):129\u2013141. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00515.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"724_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2016.07.002","volume":"81","author":"N Chuhma","year":"2017","unstructured":"Chuhma N, Mingote S, Kalmbach A, Yetnikoff L, Rayport S (2017) Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia. Biol Psychiatry 81(1):43\u201351. https:\/\/doi.org\/10.1016\/j.biopsych.2016.07.002","journal-title":"Biol Psychiatry"},{"issue":"1","key":"724_CR13","doi-asserted-by":"publisher","first-page":"16163","DOI":"10.1038\/s41598-024-66879-0","volume":"14","author":"C Cuttler","year":"2024","unstructured":"Cuttler C, Stueber A, Cooper ZD, Russo E (2024) Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep 14(1):16163. https:\/\/doi.org\/10.1038\/s41598-024-66879-0","journal-title":"Sci Rep"},{"key":"724_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejphar.2015.12.032","volume":"771","author":"S Datta","year":"2016","unstructured":"Datta S, Jamwal S, Deshmukh R, Kumar P (2016) Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. Eur J Pharmacol 771:229\u2013235. https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.032","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"724_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS, Allar\u00e0 M, Bisogno T, Petrosino S, Stott CG, Marzo D, V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163(7):1479\u20131494. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01166.x","journal-title":"Br J Pharmacol"},{"issue":"7","key":"724_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-v","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13(7):281\u2013285. https:\/\/doi.org\/10.1016\/0166-2236(90)90110-v","journal-title":"Trends Neurosci"},{"key":"724_CR17","doi-asserted-by":"publisher","unstructured":"di Giacomo V, Chiavaroli A, Recinella L, Orlando G, Cataldi A, Rapino M, Ferrante C (2020) Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes. Int J Mol Sci 21(10). https:\/\/doi.org\/10.3390\/ijms21103575","DOI":"10.3390\/ijms21103575"},{"key":"724_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1742-2094-9-71","volume":"9","author":"Y Diz-Chaves","year":"2012","unstructured":"Diz-Chaves Y, Pern\u00eda O, Carrero P, Garcia-Segura LM (2012) Prenatal stress causes alterations in the morphology of microglia and the inflammatory response of the hippocampus of adult female mice. J Neuroinflammation 9:71. https:\/\/doi.org\/10.1186\/1742-2094-9-71","journal-title":"J Neuroinflammation"},{"key":"724_CR19","doi-asserted-by":"publisher","first-page":"1045465","DOI":"10.3389\/fphar.2022.1045465","volume":"13","author":"M Dos Santos Pereira","year":"2022","unstructured":"Dos Santos Pereira M, do Nascimento GC, Bortolanza M, Michel PP, Raisman-Vozari R, Del Bel E (2022) Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Front Pharmacol 13:1045465. https:\/\/doi.org\/10.3389\/fphar.2022.1045465","journal-title":"Front Pharmacol"},{"issue":"7","key":"724_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/j.1476-5381.2011.01444.x","volume":"163","author":"H Du","year":"2011","unstructured":"Du H, Chen X, Zhang J, Chen C (2011) Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-\u03b3. Br J Pharmacol 163(7):1533\u20131549. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01444.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"724_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12640-020-00277-y","volume":"39","author":"C Echeverry","year":"2021","unstructured":"Echeverry C, Prunell G, Narbondo C, de Medina VS, Nadal X, Reyes-Parada M, Scorza C (2021) A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT. Neurotox Res 39(2):335\u2013348. https:\/\/doi.org\/10.1007\/s12640-020-00277-y","journal-title":"Neurotox Res"},{"issue":"12","key":"724_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.parkreldis.2014.09.030","volume":"20","author":"JH Friedman","year":"2014","unstructured":"Friedman JH (2014) Viewpoint: challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism Relat Disord 20(12):1325\u20131328. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.030","journal-title":"Parkinsonism Relat Disord"},{"key":"724_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-7091-9211-5_4","volume":"36","author":"CR Gerfen","year":"1992","unstructured":"Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. J Neural Transm Suppl 36:43\u201359. https:\/\/doi.org\/10.1007\/978-3-7091-9211-5_4","journal-title":"J Neural Transm Suppl"},{"issue":"5","key":"724_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopsych.2003.08.008","volume":"55","author":"C Grande","year":"2004","unstructured":"Grande C, Zhu H, Martin AB, Lee M, Ortiz O, Hiroi N, Moratalla R (2004) Chronic treatment with atypical neuroleptics induces striosomal FosB\/DeltaFosB expression in rats. Biol Psychiatry 55(5):457\u2013463. https:\/\/doi.org\/10.1016\/j.biopsych.2003.08.008","journal-title":"Biol Psychiatry"},{"issue":"5","key":"724_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mds.27630","volume":"34","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, L\u00e9vesque D (2019) Tardive dyskinesia is associated with altered putamen Akt\/GSK-3\u03b2 signaling in nonhuman primates. Mov Disord 34(5):717\u2013726. https:\/\/doi.org\/10.1002\/mds.27630","journal-title":"Mov Disord"},{"issue":"3","key":"724_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/ajhp\/zxz299","volume":"77","author":"F Khorassani","year":"2020","unstructured":"Khorassani F, Luther K, Talreja O (2020) Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. Am J Health Syst Pharm 77(3):167\u2013174. https:\/\/doi.org\/10.1093\/ajhp\/zxz299","journal-title":"Am J Health Syst Pharm"},{"key":"724_CR28","doi-asserted-by":"publisher","first-page":"173114","DOI":"10.1016\/j.pbb.2021.173114","volume":"202","author":"M Kimura","year":"2021","unstructured":"Kimura M, Oda Y, Kimura H, Nangaku M, Hirose Y, Niitsu T, Iyo M (2021) Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol. Pharmacol Biochem Behav 202:173114. https:\/\/doi.org\/10.1016\/j.pbb.2021.173114","journal-title":"Pharmacol Biochem Behav"},{"key":"724_CR29","doi-asserted-by":"publisher","first-page":"135976","DOI":"10.1016\/j.neulet.2021.135976","volume":"757","author":"M Maredia","year":"2021","unstructured":"Maredia M, Hamilton J, Thanos PK (2021) A high-fat diet, but not haloperidol or olanzapine administration, increases activated microglial expression in the rat brain. Neurosci Lett 757:135976. https:\/\/doi.org\/10.1016\/j.neulet.2021.135976","journal-title":"Neurosci Lett"},{"issue":"9","key":"724_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/070674370505000907","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 50(9):541\u2013547. https:\/\/doi.org\/10.1177\/070674370505000907","journal-title":"Can J Psychiatry"},{"key":"724_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnmol.2015.00078","volume":"8","author":"K Minatohara","year":"2015","unstructured":"Minatohara K, Akiyoshi M, Okuno H (2015) Role of Immediate-Early Genes in Synaptic Plasticity and Neuronal Ensembles Underlying the Memory Trace. Front Mol Neurosci 8:78. https:\/\/doi.org\/10.3389\/fnmol.2015.00078","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"724_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","volume":"110","author":"LA Moraes","year":"2006","unstructured":"Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110(3):371\u2013385. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.08.007","journal-title":"Pharmacol Ther"},{"issue":"2","key":"724_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.120.000340","volume":"376","author":"R Nachnani","year":"2021","unstructured":"Nachnani R, Raup-Konsavage WM, Vrana KE (2021) The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther 376(2):204\u2013212. https:\/\/doi.org\/10.1124\/jpet.120.000340","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"724_CR34","doi-asserted-by":"publisher","first-page":"e145632","DOI":"10.1172\/jci.insight.145632","volume":"6","author":"K Nagaoka","year":"2021","unstructured":"Nagaoka K, Nagashima T, Asaoka N, Yamamoto H, Toda C, Kayanuma G, Siswanto S, Funahashi Y, Kuroda K, Kaibuchi K, Mori Y, Nagayasu K, Shirakawa H, Kaneko S (2021) Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. JCI insight 6(10):e145632. https:\/\/doi.org\/10.1172\/jci.insight.145632","journal-title":"JCI insight"},{"key":"724_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2018.00632","volume":"9","author":"G Navarro","year":"2018","unstructured":"Navarro G, Varani K, Reyes-Resina I, S\u00e1nchez de Medina V, Rivas-Santisteban R, S\u00e1nchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI, Borea PA, Nadal X, Franco R (2018) Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol 9:632. https:\/\/doi.org\/10.3389\/fphar.2018.00632","journal-title":"Front Pharmacol"},{"issue":"3","key":"724_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002826-198409000-00005","volume":"7","author":"T Nishikawa","year":"1984","unstructured":"Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y (1984) Clonidine therapy for tardive dyskinesia and related syndromes. Clin Neuropharmacol 7(3):239\u2013245. https:\/\/doi.org\/10.1097\/00002826-198409000-00005","journal-title":"Clin Neuropharmacol"},{"key":"724_CR37","doi-asserted-by":"publisher","first-page":"204512531984788","DOI":"10.1177\/2045125319847882","volume":"9","author":"RS Patel","year":"2019","unstructured":"Patel RS, Mansuri Z, Motiwala F, Saeed H, Jannareddy N, Patel H, Zafar MK (2019) A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol 9:2045125319847882. https:\/\/doi.org\/10.1177\/2045125319847882","journal-title":"Ther Adv Psychopharmacol"},{"key":"724_CR38","unstructured":"Paxinos G, Franklin KBJ (2008) The mouse brain in stereotaxic coordinates, 3rd edn. Academic"},{"issue":"9","key":"724_CR39","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s11064-016-1961-6","volume":"41","author":"LR Peroza","year":"2016","unstructured":"Peroza LR, Schaffer LF, De Freitas CM, Leal CQ, Ferrari MC, Duarte MM, Fachinetto R (2016) Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics. Neurochem Res 41(9):2481\u20132489. https:\/\/doi.org\/10.1007\/s11064-016-1961-6","journal-title":"Neurochem Res"},{"issue":"2","key":"724_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/1098-2396(200102)39:2<122::AID-SYN3>3.0.CO;2-R","volume":"39","author":"JJ Rodr\u00edguez","year":"2001","unstructured":"Rodr\u00edguez JJ, Garcia DR, Nakabeppu Y, Pickel VM (2001) FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse 39(2):122\u2013132. https:\/\/doi.org\/10.1002\/1098-2396(200102)39:2%3C122::AID-SYN3%3E3.0.CO;2-R","journal-title":"Synapse"},{"key":"724_CR41","doi-asserted-by":"publisher","first-page":"173193","DOI":"10.1016\/j.pbb.2021.173193","volume":"206","author":"J R\u00f6pke","year":"2021","unstructured":"R\u00f6pke J, Ferreira-Vieira TH, Iglesias LP, Asth L, Ribeiro FM, Moreira FA (2021) Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia. Pharmacol Biochem Behav 206:173193. https:\/\/doi.org\/10.1016\/j.pbb.2021.173193","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"724_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14737175.2017.1361322","volume":"17","author":"H Salem","year":"2017","unstructured":"Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL (2017) Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother 17(9):883\u2013894. https:\/\/doi.org\/10.1080\/14737175.2017.1361322","journal-title":"Expert Rev Neurother"},{"key":"724_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2016.06.003","volume":"148","author":"J Shi","year":"2016","unstructured":"Shi J, Tan YL, Wang ZR, An HM, Li J, Wang YC, Zhang XY (2016) Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacol Biochem Behav 148:53\u201358. https:\/\/doi.org\/10.1016\/j.pbb.2016.06.003","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"724_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s002130000532","volume":"152","author":"S Silvestri","year":"2000","unstructured":"Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152(2):174\u2013180. https:\/\/doi.org\/10.1007\/s002130000532","journal-title":"Psychopharmacology"},{"key":"724_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbi.2018.09.014","volume":"74","author":"AB Sonego","year":"2018","unstructured":"Sonego AB, Prado DS, Vale GT, Sepulveda-Diaz JE, Cunha TM, Tirapelli CR, Guimar\u00e3es FS (2018) Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPAR\u03b3 receptors. Brain Behav Immun 74:241\u2013251. https:\/\/doi.org\/10.1016\/j.bbi.2018.09.014","journal-title":"Brain Behav Immun"},{"issue":"1","key":"724_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852917000621","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM (2018) Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less go and more stop from the motor striatum for robust therapeutic effects. CNS Spectr 23(1):1\u20136. https:\/\/doi.org\/10.1017\/S1092852917000621","journal-title":"CNS Spectr"},{"issue":"4","key":"724_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/can.2020.0159","volume":"6","author":"NL Stone","year":"2021","unstructured":"Stone NL, England TJ, O\u2019Sullivan SE (2021) Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood-Brain Barrier Under Ischemic Conditions. Cannabis Cannabinoid Res 6(4):315\u2013326. https:\/\/doi.org\/10.1089\/can.2020.0159","journal-title":"Cannabis Cannabinoid Res"},{"issue":"10","key":"724_CR48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/mds.25107","volume":"27","author":"JT Teo","year":"2012","unstructured":"Teo JT, Edwards MJ, Bhatia K (2012) Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 27(10):1205\u20131215. https:\/\/doi.org\/10.1002\/mds.25107","journal-title":"Mov Disord"},{"issue":"5","key":"724_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-2007-1017272","volume":"19","author":"J Tripodianakis","year":"1986","unstructured":"Tripodianakis J, Markianos M (1986) Clonidine trial in tardive dyskinesia. Therapeutic response, MHPG, and plasma DBH. Pharmacopsychiatry 19(5):365\u2013367. https:\/\/doi.org\/10.1055\/s-2007-1017272","journal-title":"Pharmacopsychiatry"},{"key":"724_CR50","doi-asserted-by":"publisher","first-page":"834129","DOI":"10.3389\/fphar.2021.834129","volume":"12","author":"EE Tsermpini","year":"2021","unstructured":"Tsermpini EE, Reden\u0161ek S, Dol\u017ean V (2021) Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies. Front Pharmacol 12:834129. https:\/\/doi.org\/10.3389\/fphar.2021.834129","journal-title":"Front Pharmacol"},{"issue":"3","key":"724_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s0149-7634(02)00008-8","volume":"26","author":"P Turrone","year":"2002","unstructured":"Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26(3):361\u2013380. https:\/\/doi.org\/10.1016\/s0149-7634(02)00008-8","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"724_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","volume":"165","author":"P Turrone","year":"2003","unstructured":"Turrone P, Remington G, Kapur S, Nobrega JN (2003) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 165(2):166\u2013171. https:\/\/doi.org\/10.1007\/s00213-002-1259-z","journal-title":"Psychopharmacology"},{"issue":"1","key":"724_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","volume":"12","author":"S Valdeolivas","year":"2015","unstructured":"Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Mu\u00f1oz E, Sagredo O (2015) Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12(1):185\u2013199. https:\/\/doi.org\/10.1007\/s13311-014-0304-z","journal-title":"Neurotherapeutics"},{"key":"724_CR54","doi-asserted-by":"publisher","first-page":"871962","DOI":"10.3389\/fphys.2022.871962","volume":"13","author":"VL Vernail","year":"2022","unstructured":"Vernail VL, Bingaman SS, Silberman Y, Raup-Konsavage WM, Vrana KE, Arnold AC (2022) Acute Cannabigerol Administration Lowers Blood Pressure in Mice. Front Physiol 13:871962. https:\/\/doi.org\/10.3389\/fphys.2022.871962","journal-title":"Front Physiol"},{"issue":"6","key":"724_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0278-5846(88)90081-4","volume":"12","author":"R Wilbur","year":"1988","unstructured":"Wilbur R, Kulik FA, Kulik AV (1988) Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuro-psychopharmacol Biol Psychiatry 12(6):849\u2013864. https:\/\/doi.org\/10.1016\/0278-5846(88)90081-4","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"issue":"1\u20132","key":"724_CR56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0006-8993(89)90387-9","volume":"484","author":"W Zhang","year":"1989","unstructured":"Zhang W, Tilson H, Stachowiak MK, Hong JS (1989) Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Res 484(1\u20132):389\u2013392. https:\/\/doi.org\/10.1016\/0006-8993(89)90387-9","journal-title":"Brain Res"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-024-00724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-024-00724-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-024-00724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:53:13Z","timestamp":1743310393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-024-00724-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s12640-024-00724-0","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JA Crippa is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) \u2013 National Health and Medical Research Council (NHMRC). JA Crippa has received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JA Crippa, Hallak JEC and Guimar\u00e3es FS are coinventors of the patent \u201cFluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO\/2014\/108899. International Application No.: PCT\/IL2014\/050023,\u201d Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimar\u00e3es FS, Crippa JA, Breuer A). Universidade de S\u00e3o Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to \u201cdevelop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson\u2019s disease, and anxiety disorders.\u201d JA Crippa, Hallak JEC and Guimar\u00e3es FS are coinventors of the patent \u201cCannabinoid-containing oral pharmaceutical composition, method for preparing and using same,\u201d INPI on September 16th, 2016 (BR 112018005423-2). JA Crippa is a consultant and\/or has received speaker fees and\/or sits on the advisory board and\/or receives research funding from Janssen-Cilag, Torrent Pharm, Prati-Donaduzzi, PurMed Global, DSM Pharm, EaseLabs, Mantecorp, Greencare, ArtMed and BrainsBio Pharm over the past 3 years.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2"}}